Abstracts Archive - Page 134 of 2607 - ACR Meeting Abstracts

Abstract Number: 1916 • ACR Convergence 2025
Adherence to cervical cancer screening programs in women with Systemic Lupus Erythematosus
Carmen Lasa Teja¹, Carolina Aguirre-Portilla², Virginia Portilla González³, Carmen Bejerano-Herreria², Alfonso Corrales-Martínez⁴ and Ricardo Blanco⁵, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, ⁴Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ⁵Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Women with Systemic Lupus Erythematosus (SLE) are at a higher risk of persistent HPV infection and developing premalignant cervical lesions and cervical cancer. High-risk…
Abstract Number: 1995 • ACR Convergence 2025
The Prevalence of Multimorbidity and Polypharmacy Among US Adults with Gout: A General Population-Based Study
Chio Yokose¹, Natalie McCormick², Jiaqi Wang², Sharan Rai³, leo lu⁴ and Hyon K. Choi⁵, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Gout is an inflammatory-metabolic condition that is associated with a heavy burden of cardiovascular-kidney-metabolic (CKM) comorbidities. Accordingly, multimorbidity and polypharmacy are important considerations which…
Abstract Number: 1990 • ACR Convergence 2025
Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout
Alex Tinianow¹, Saiajay Chigurupati¹, Ethan Carey¹, Jiaqi Wang², Sharan Rai³, Gregory Challener⁴, Hyon K. Choi⁵, Philip Riches⁶, Natalie McCormick¹ and Chio Yokose⁷, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, BOston, ³Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁴MGH, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶NHS Lothian, Edinburgh, UK, Edinburgh, United Kingdom, ⁷Massachusetts General Hospital, Waltham, MA
Background/Purpose: Rheumatology guidelines endorse a treat-to-target (TTT) approach targeting serum urate (SU) < 6 mg/dL among patients with gout who qualify for urate-lowering therapy (ULT).…
Abstract Number: 2001 • ACR Convergence 2025
Characteristics of Gout Flares Over Time with Treat-to-Target Urate-Lowering Therapy Use
Jason Yang¹, Ted Mikuls², Harlan Sayles², Michael Pillinger³, Jeff Newcomb², Bridget Kramer², Anne Davis-Karim⁴, Mary Brophy⁵, Ryan Ferguson⁵, Paul Palevsky⁶, James O'Dell² and Tuhina Neogi⁷, ¹Boston Medical Center, Boston, MA, ²University of Nebraska Medical Center, Omaha, NE, ³New York University Grossman School of Medicine, New York,, NY, ⁴VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁵VA Cooperative Studies Program Coordinating Center, Boston, MA, ⁶VA Pittsburgh Healthcare System, Pittsburgh, PA, ⁷Boston University School of Medicine, Boston, MA
Background/Purpose: Gout flares are an important treatment outcome in gout. Although flares are typically assessed by occurrence (yes/no) or a simple count in trials of…
Abstract Number: 1795 • ACR Convergence 2025
Trends and Disparities in Osteoarthritis-Related Mortality in the United States: A 21-Year Analysis (1999-2020)
muzamil Khan¹, Swetha Balaji², Ayesha Cheema³, Wajdan Ahmad³, Dhruv gandhi⁴ and Steven Golombek⁵, ¹George Washington University School of Medicine and Health Sciences, Washington D.C, ²New York Medical College at St. Mary's General Hospital and St. Clare's Health, Parsippany-Troy Hills, NJ, ³Al Tibri Medical College, Karachi, Pakistan, ⁴St. Francis Medical Center, Monroe, ⁵NYMC at St. Mary's General Hospital and St. Clare's Health, Dover
Background/Purpose: Osteoarthritis/arthrosis is an aging-related disease which is associated with significant morbidity in the United States. However, epidemiological data regarding osteoarthritis-associated mortality in the United…
Abstract Number: 1785 • ACR Convergence 2025
Soluble CD14 Amplifies Chondrocyte Inflammatory Responses to Lipopolysaccharide and Is Targetable by Anti-CD14 Therapy
Anna Rapp¹, Kate Sharp¹, Baofeng Hu² and Carla Scanzello¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Wynnewood, PA
Background/Purpose: Osteoarthritis (OA) is characterized by a pro-inflammatory joint microenvironment, including elevated levels of endogenous pattern recognition receptor ligands in synovial fluid. Notably, both lipopolysaccharide…
Abstract Number: 1973 • ACR Convergence 2025
Evaluating the Impact of Clinical Pharmacist Integration on Patient Care Outcomes in a Private Rheumatology Clinic
Madana Kamineni¹, Janelle Vircks¹, Jessica Lynton¹, Clarisse Purvis¹ and Brittany Panico², ¹Optum, Gilbert, AZ, ²Summit Rheumatology, Gilbert, AZ
Background/Purpose: Existing data demonstrate that clinical pharmacist integration in rheumatology clinics improves provider satisfaction, patient outcomes, medication adherence, and RAPID-3 (Routine Assessment of Patient Index…
Abstract Number: 1014 • ACR Convergence 2025
Factors Associated with Fibromyalgia Diagnosis amongst People Meeting Criteria: Results from UK Biobank
Sung-A Kim, Gary Macfarlane and Marcus Beasley, University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: The diagnosis of fibromyalgia (FM) is challenging due to its reliance on patient-reported symptoms, the absence of definitive biomarkers, and numerous overlapping comorbidities. Discrepancies…
Abstract Number: 1552 • ACR Convergence 2025
Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
Zahi Touma¹, Ian Bruce², Richard Furie³, Eric Morand⁴, Raj Tummala⁵, Shelly Chandran⁶, Gabriel Abreu⁷, Jacob Knagenhjelm⁷, Cathy Emmas⁸, Lyra Agustin⁸, Alessandra Venerus⁹, Tarana Mehdikhanova¹⁰, Zheyuan Yang¹⁰ and Miina Waratani⁸, ¹University of Toronto, Toronto, ON, Canada, ²Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁵AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, Gaithersburg, MD, ⁶AstraZeneca, Medical & Scientific Affairs, R&I, Mississauga, ON, Canada, ⁷AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden, ⁸AstraZeneca, BioPharmaceuticals Medical, Cambridge, United Kingdom, ⁹IQVIA, EMEA Real World Methods and Evidence Generation, Milan, Italy, ¹⁰IQVIA, EMEA Real World Methods and Evidence Generation, London, United Kingdom
Background/Purpose: Patients with systemic lupus erythematosus (SLE) can develop cardiovascular (CV) damage (angina, myocardial infarction, ventricular dysfunction, valvular disease, or pericarditis for 6 months/pericardiectomy) particularly…
Abstract Number: 1810 • ACR Convergence 2025
Destabilized Treg Cells Predominant in Severe Forms of Juvenile Idiopathic Arthritis
Ki Pui Lam¹, Claudia Harris², Jennifer Cheng³, Lwiza AitDowd⁴, Maryam Ashoor⁵, Ahmad Bakhsh³, Carrie Bryant³, Siobhan Case⁶, Mia Chandler³, Joyce Chang³, Ezra Cohen⁷, Fatma Dedeoglu³, Olha Halyabar⁸, Jonathan Hausmann⁹, Melissa Hazen³, Sonia Iosim¹⁰, Liyoung Kim¹¹, Jeffrey Lo³, Mindy Lo³, Emma Materne³, Esra Meidan¹², Megan Perron¹³, Helene Powers¹⁰, Mary Beth Son³, Holly Wobma³, Margaret Chang³, Pui Lee¹⁴, Peter Nigrovic¹¹ and Lauren Henderson¹⁵, ¹Division of Immunology, Boston Childrens Hospital, Harvard Medical School, Boston, MA, ²Division of Immunology, Boston Childrens Hospital, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Boston Children's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Brookline, MA, ⁶UpToDate, Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA, ⁷Bmc, NEEDHAM, MA, ⁸Children's Hospital/Boston Medical Center, Newton, MA, ⁹Boston Children's Hospital / Massachusetts General Hospital, Cambridge, MA, ¹⁰Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, ¹¹Boston Children's Hospital, Brookline, MA, ¹²Boston Children's Hospital, Somerville, MA, ¹³Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Natick, MA, ¹⁴Boston Children's Hospital, Newton, MA, ¹⁵Boston Children's Hospital, Watertown, MA
Background/Purpose: T peripheral helper (Tph) cells stimulate excessive B cell responses in the joints of patients with autoantibody-positive arthritis, including seropositive RA in adults and…
Abstract Number: 1828 • ACR Convergence 2025
CD14+CXCL10+Monocytes Remodel the Peripheral Immune Network in sJIA via UBE2D1-Driven Inflammatory Programming
Xuemei Tang¹, Qiang Luo², Jun Yang³, Haiguo Yu⁴, Xinglin Wu¹, Xiwen Luo⁵, Xi Yang⁵, Zhiyong Zhang⁵, Yunfei An⁵, Xiaodong Zhao¹ and Hongmei Song⁶, ¹Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic), ²Department of Rheumatology and Immunology, Children’s Hospital of Chongqing Medical University, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China (People's Republic), ³Rheumatology and Immunology Department of Shenzhen Children's Hospital, Shenzhen, ⁵¹⁸¹⁰⁰, China., Shenzhen, China (People's Republic), ⁴Department of Rheumatology and Immunology, Nanjing Children's Hospital, Nanjing, ²¹⁰⁰⁰⁰, China., Nanjing, China (People's Republic), ⁵Department of Rheumatology & Immunology, Children’s Hospital of Chongqing Medical University, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China., Chongqing, China (People's Republic), ⁶Pediatric Department of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, ¹⁰⁰⁰⁰⁰, China., Beijing, China (People's Republic)
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disorder characterized by systemic immune dysregulation. However, reliable biomarkers to predict its unpredictable disease course are…
Abstract Number: 1988 • ACR Convergence 2025
Advancing Vascular Assessment: Combining NIRS-VOT and Ultrasound-Based Brachial Artery Diameter for Improved Diagnostics in Healthy Controls and APS
Soongho Park¹, Julie Mathew¹, Sharon Osgood², Claudia Gomez¹, Eric Leifer¹, Ecem Sevim¹ and Yogendra Kanthi³, ¹NIH, Bethesda, ²NHLBI/NIH, Bethesda, ³National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: Near-Infrared Spectroscopy combined with Vascular Occlusion Test (NIRS-VOT) is a non-invasive diagnostic method for assessing microvascular function. However, its diagnostic accuracy is often limited…
Abstract Number: 1024 • ACR Convergence 2025
Mortality In Progressive Pulmonary Fibrosis Associated to Autoimmune Diseases: NEREA Registry
Marta Ruiz-Valdepeñas Almansa¹, CLARA DE MIGUEL², DALIFER FREITES³, Cristina Vadillo Font⁴, Maria asuncion Nieto⁴, Olga Sanchez Pernaute⁵, fredeswinda Romero-Bueno⁶, Mª Jesus Rodriguez-Nieto⁷, Rosalia Laporta⁸, Hilda Godoy Tundidor⁹, Jesús Loarce¹⁰, Juan A Rigual¹¹ and lydia Abasolo Alcazar¹², ¹HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, ²HOSPITAL CLINICO SAN CARLOS, Madrid, Madrid, Spain, ³Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁴Hospital Clínico S Carlos, Madrid, Spain, ⁵Clinica Universidad de Navarra, Madrid, Madrid, Spain, ⁶University Hospital Fundación Jiménez Díaz"", Madrid, Spain, ⁷Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, ⁸Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ⁹Hospital Universitario puerta de hierro, Madrid, Spain, ¹⁰HOSPITAL RAMÓN Y CAJAL, MADRID, Madrid, Spain, ¹¹Hospital Ramón y Cajal, Madrid, Spain, ¹²IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Autoimmune interstitial lung disease (ILD) may arise in various autoimmune rheumatic diseases (ARD). Some patients develop ILD with systemic symptoms and autoantibodies without fulfilling…
Abstract Number: 1568 • ACR Convergence 2025
A Novel Endothelial Cell Profiling Assay to Identify Systemic Sclerosis Patient Characteristics at the Endothelial Cell Level
Eva Hoekstra¹, Rudmer Postma¹, Nils Steinz², Wieke van Oostveen¹, Roel Bijkerk¹, Vincent van Duinen², Rachel Knevel², Tom Huizinga², Anton jan van Zonneveld¹, Jeska de Vries-Bouwstra² and Cynthia Fehres¹, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Vasculopathy, a hallmark clinical feature in systemic sclerosis (SSc), is a consequence of endothelial cell (EC) damage and dysfunction and might precede tissue fibrosis.…
Abstract Number: 1994 • ACR Convergence 2025
Pharmacokinetics of Ready-to-Use Pegloticase Formulation Compared to Standard Pegloticase Dosing: Data from the AGILE Study
Orrin Troum¹, John Botson², Afroz S. Mohammad³, Xiaoqing Yang⁴, Nathan Roe⁵, Supra Verma⁶ and Brian Lamoreaux⁷, ¹Providence Health Care/Doctor's of St John's (MDSJ) Santa Monica, CA, Santa Monica, CA, ²Orthopedic Physicians Alaska, Anchorage, AK, ³Amgen Inc, Deerfield, ⁴Amgen, Seattle, WA, ⁵Horizon Therapeutics, Boise, ID, ⁶Horizon Therapeutics, Newport Beach, CA, ⁷Amgen, Inc., Deerfield, IL
Background/Purpose: Pegloticase is approved for uncontrolled gout as 8-mg infusions admixed in 250 cc of normal saline over 120 minutes or more administered every 2…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].